Dr. Farkad Ezzet Will Present on the Strategic Value of Literature Modeling to Assess Disease Progression and Drug Attributes in Clinical Development
MOUNTAIN VIEW, Calif., June 17 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Farkad Ezzet, Ph.D., senior scientist, Pharsight Strategic Consulting Services, has been invited to speak to members of the biotechnology and pharmaceutical industries attending the 2008 AAPS National Biotechnology Conference. The Congress will be held at the Metro Toronto Convention Center in Toronto, Canada from June 22-25, 2008. Dr. Ezzet will present on June 24, joining other leading industry experts in a roundtable session on the utilization of disease progression models in clinical drug development.
Dr. Ezzet's presentation, entitled "The Role of Literature-Based Disease Progression Models to Support Knowledge Management and Decision-Making in Clinical Drug Development," will describe how model-based approaches that incorporate public-source data from the scientific literature can provide quantitative insights into disease progression and predictive assessments of a new drug candidate's likely product profile versus competing treatments. Dr. Ezzet's presentation will feature an illustrative case study for the treatment of obesity, and will also cover important considerations for using literature-based modeling approaches to enhance strategic decision-making in drug development.
"Literature-based models provide a quantitative assessment of the
competitive landscape and offer a framework to address important clinical
development program q
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved